We are live on ! Find out more
STRO icon

Sutro Biopharma
STRO

117 hedge funds and large institutions have $593M invested in Sutro Biopharma in 2021 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 44 increasing their positions, 39 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 39

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

0.02% less ownership

Funds ownership: 8.63% → 8.62% (-0.02%)

3% less funds holding

Funds holding: 120 → 117 (-3)

18% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 17

21% less capital invested

Capital invested by funds: $753M → $593M (-$160M)

99% less call options, than puts

Call options by funds: $24K | Put options by funds: $1.99M

Holders
117
Holders Change
-3
Holders Change %
-2.5%
% of All Funds
1.8%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
14
Increased
44
Reduced
39
Closed
17
Calls
$24K
Puts
$1.99M
Net Calls
-$1.96M
Net Calls Change
-$1.97M

Top Buyers

Rank Fund Capital Flow
1
EAM
Eventide Asset Management
Massachusetts
+$6.06M
2
Franklin Resources
Franklin Resources
California
+$5.65M
3
FM
Frazier Management
Washington
+$5.51M
4
SCM
Suvretta Capital Management
New York
+$3.66M
5
OM
Opaleye Management
Massachusetts
+$2.55M

Top Sellers

Rank Fund Capital Flow
1
Loomis, Sayles & Company
Loomis, Sayles & Company
Massachusetts
-$8.13M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$7.08M
3
WP
Woodline Partners
California
-$4.15M
4
Invesco
Invesco
Georgia
-$3.21M
5
N
Nuveen
North Carolina
-$3.15M
Name Holding Trade Value Shares
Change 		Change in
Stake
PCM
26
Pentwater Capital Management
Florida
$3.42M +$358K +2,000 +10%
Nomura Holdings
27
Nomura Holdings
Japan
$3.3M -$5.55K -31 -0.1%
PHP
28
Parkman Healthcare Partners
Connecticut
$3.29M +$1.04M +5,783 +35%
Janus Henderson Group
29
Janus Henderson Group
United Kingdom
$3.28M +$58K +324 +1%
AllianceBernstein
30
AllianceBernstein
Tennessee
$3.21M +$195K +1,089 +5%
Verition Fund Management
31
Verition Fund Management
Connecticut
$2.75M +$390K +2,176 +13%
N
32
Nuveen
North Carolina
$2.71M -$3.15M -17,606 -49%
AIIC
33
AJU IB Investment Company
South Korea
$2.6M – – –
Victory Capital Management
34
Victory Capital Management
Texas
$2.59M +$661K +3,688 +27%
Invesco
35
Invesco
Georgia
$2.47M -$3.21M -17,902 -52%
Adage Capital Partners
36
Adage Capital Partners
Massachusetts
$2.38M -$2.06M -11,500 -42%
Bank of New York Mellon
37
Bank of New York Mellon
New York
$2.23M -$309K -1,726 -10%
Millennium Management
38
Millennium Management
New York
$2.17M -$1.24M -6,894 -32%
PAM
39
Panagora Asset Management
Massachusetts
$2.16M -$157K -878 -6%
Neuberger Berman Group
40
Neuberger Berman Group
New York
$2.14M -$1.33M -7,417 -34%
Acadian Asset Management
41
Acadian Asset Management
Massachusetts
$2.14M -$691K -3,857 -21%
IBT
42
International Biotechnology Trust
United Kingdom
$2.07M – – –
KCM
43
Kennedy Capital Management
Missouri
$1.9M -$69.2K -386 -3%
Bank of America
44
Bank of America
North Carolina
$1.73M +$1.44M +8,022 +222%
Two Sigma Investments
45
Two Sigma Investments
New York
$1.68M -$2.05M -11,440 -50%
ECM
46
Endurant Capital Management
California
$1.66M +$2M +11,180 New
Charles Schwab
47
Charles Schwab
California
$1.63M +$30.1K +168 +2%
Hudson Bay Capital Management
48
Hudson Bay Capital Management
Connecticut
$1.51M +$923K +5,150 +103%
Two Sigma Advisers
49
Two Sigma Advisers
New York
$1.4M -$1.07M -6,000 -39%
Rafferty Asset Management
50
Rafferty Asset Management
New York
$1.21M +$455K +2,542 +46%
1
2
3 4 5

STRO Hedge Fund Activity: Q4 2021 in Review

117 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q4 2021, worth a combined $593M — down 21% from $753M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of STRO and 14 opened new positions — a net loss of 3 holders — while 39 trimmed existing stakes and 44 added.

The largest buyer was Eventide Asset Management, adding an estimated $6.06M. The largest seller was Loomis, Sayles & Company, cutting an estimated $8.13M.

  • 117 institutional investors held Sutro Biopharma (STRO) as of Q4 2021, down from 120 in Q3 2021.
  • Funds reported $593M of Sutro Biopharma stock for Q4 2021, down 21% quarter-over-quarter.
  • 14 funds opened new Sutro Biopharma positions in Q4 2021 and 17 closed out, a net change of -3 holders.
  • The largest Sutro Biopharma buyer in Q4 2021 was Eventide Asset Management, an estimated $6.06M added.
  • The largest Sutro Biopharma seller in Q4 2021 was Loomis, Sayles & Company, an estimated $8.13M sold.

Based on aggregated 13F filings for Q4 2021.